2017
DOI: 10.1016/s0016-5085(17)30571-1
|View full text |Cite
|
Sign up to set email alerts
|

Phase III Randomized, Double-Blind, Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab (INX) in Patients with Active Crohn's Disease: Early Efficacy and Safety Results

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 11 publications
references
References 0 publications
0
0
0
Order By: Relevance